Skip to content
DraconiticResearch
Search Sources API
197,693 studies31 sourcesUpdated 41 min ago
Peer-reviewedCC BY-NC-NDInternal Medicine

Real-world Diagnosis and Testing of Acquired Hemophilia A in Japan: A Web-based Physician Survey

Abstract

Objective Acquired hemophilia A (AHA) is a rare and often severe bleeding disorder caused by autoantibodies against coagulation factor VIII (FVIII). Both the prompt diagnosis and treatment of patients with AHA are essential. Data on Japanese AHA diagnostic delay are lacking; therefore, this study aimed to determine the time to AHA diagnosis in Japan, as well as to identify factors influencing the time from presentation to diagnosis. Methods This web-based, prospective, observational study surveyed physicians in Japan who had diagnosed or treated patients with AHA. The time from bleeding onset to diagnosis was the primary endpoint, with diagnostic testing barriers as the secondary endpoints. Results Of the 322 physicians who accessed the survey, 112 were included in the study. The time from bleeding onset to referral and from referral to diagnosis was ≥8 days in 31.3% (n=35) and 23.2% (n=26) of cases, respectively. The tests most commonly conducted in-hospital were activated partial thromboplastin time (aPTT) and aPTT cross-mixing tests (85.7% and 73.2%, respectively), for which results typically took <1 day to obtain. FVIII activity and FVIII inhibitor tests were more often outsourced, and when performed in-hospital, the results took ≥2 days in over 25% of cases. Across the tests surveyed, 41.7-76.2% of physicians noted difficulty in interpreting test results as a reason for AHA diagnosis delay. Conclusion More efficient diagnostic procedures and enhanced physician education and awareness are needed to shorten AHA diagnosis times in Japan.

Related

  1. Refractory Obstetric Hemorrhage As the Initial Presentation of Acquired Hemophilia: A Case Report on the Diagnostic Limitations of Viscoelastic Testing.
    Maria Alaciel Galvan Merlos, Maria Dioselina Ruiz Barrera, Cristina Elizabeth Madera Maldonado +4
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  2. Acute Groin Pain Revealing Acquired Hemophilia A: A Case Report of Spontaneous Iliopsoas Hematoma
    Sara Senne, Konstantinos Loukidis, Christophe Hälg +2
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Case Report: Acquired hemophilia A presenting with recurrent arthritis-like joint swelling and musculoskeletal hematomas—a focused literature review
    Jing Zhang, Lina Zhang, Sheng-Guang Li +5
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. [Acquired hemophilia A associated with bullous pemphigoid and multiple myeloma: a case report].
    Sourdeau É, Clauser S, Prud'Homme R +2
    Annales de Biologie CliniquePeer-reviewedCC BY-NC-NDFull text6 citedGeneral biologyGeneral medicineHAL
  5. Managing Pediatric Acquired Hemophilia A When Guideline-Recommended Bypassing Agents Are Unavailable: A Case Report
    Li Zhang, Xiao-Li Guo, Jian-Wen Xiao +1
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full textGeneral medicineCrossrefEurope PMC
BibTeX
@article{seki2026realworld,
  title = {{Real-world Diagnosis and Testing of Acquired Hemophilia A in Japan: A Web-based Physician Survey}},
  author = {Yoshinobu Seki and Madoka Go and Masahiro Ieko},
  journal = {Internal Medicine},
  year = {2026},
  month = aug,
  doi = {10.2169/internalmedicine.6310-25},
  url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/15/65_6310-25/_article},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Real-world Diagnosis and Testing of Acquired Hemophilia A in Japan: A Web-based Physician Survey
AU  - Yoshinobu Seki
AU  - Madoka Go
AU  - Masahiro Ieko
PY  - 2026
DA  - 2026/08/01
JO  - Internal Medicine
DO  - 10.2169/internalmedicine.6310-25
UR  - https://www.jstage.jst.go.jp/article/internalmedicine/65/15/65_6310-25/_article
AB  - Objective Acquired hemophilia A (AHA) is a rare and often severe bleeding disorder caused by autoantibodies against coagulation factor VIII (FVIII). Both the prompt diagnosis and treatment of patients with AHA are essential. Data on Japanese AHA diagnostic delay are lacking; therefore, this study aimed to determine the time to AHA diagnosis in Japan, as well as to identify factors influencing the time from presentation to diagnosis. Methods This web-based, prospective, observational study surveyed physicians in Japan who had diagnosed or treated patients with AHA. The time from bleeding onset to diagnosis was the primary endpoint, with diagnostic testing barriers as the secondary endpoints. Results Of the 322 physicians who accessed the survey, 112 were included in the study. The time from bleeding onset to referral and from referral to diagnosis was ≥8 days in 31.3% (n=35) and 23.2% (n=26) of cases, respectively. The tests most commonly conducted in-hospital were activated partial thromboplastin time (aPTT) and aPTT cross-mixing tests (85.7% and 73.2%, respectively), for which results typically took <1 day to obtain. FVIII activity and FVIII inhibitor tests were more often outsourced, and when performed in-hospital, the results took ≥2 days in over 25% of cases. Across the tests surveyed, 41.7-76.2% of physicians noted difficulty in interpreting test results as a reason for AHA diagnosis delay. Conclusion More efficient diagnostic procedures and enhanced physician education and awareness are needed to shorten AHA diagnosis times in Japan.
SN  - 1349-7235
SN  - 0918-2918
ER  -